KR102190005B1 - Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 - Google Patents

Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 Download PDF

Info

Publication number
KR102190005B1
KR102190005B1 KR1020157007572A KR20157007572A KR102190005B1 KR 102190005 B1 KR102190005 B1 KR 102190005B1 KR 1020157007572 A KR1020157007572 A KR 1020157007572A KR 20157007572 A KR20157007572 A KR 20157007572A KR 102190005 B1 KR102190005 B1 KR 102190005B1
Authority
KR
South Korea
Prior art keywords
grpr
antagonist
cancer
chelator
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157007572A
Other languages
English (en)
Korean (ko)
Other versions
KR20150090886A (ko
Inventor
테오도시아 마이나-노크
베르톨드 아써 노크
마리온 데 종 헨드릭스
Original Assignee
어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. filed Critical 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Priority to KR1020207034970A priority Critical patent/KR102314293B1/ko
Publication of KR20150090886A publication Critical patent/KR20150090886A/ko
Application granted granted Critical
Publication of KR102190005B1 publication Critical patent/KR102190005B1/ko
Assigned to 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. reassignment 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. 권리의 전부이전등록 Assignors: 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020157007572A 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제 Active KR102190005B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207034970A KR102314293B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
US61/705,513 2012-09-25
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034970A Division KR102314293B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Publications (2)

Publication Number Publication Date
KR20150090886A KR20150090886A (ko) 2015-08-06
KR102190005B1 true KR102190005B1 (ko) 2020-12-15

Family

ID=49887190

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157007572A Active KR102190005B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
KR1020207034970A Active KR102314293B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207034970A Active KR102314293B1 (ko) 2012-09-25 2013-09-25 Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102190005B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL276300B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
KR20220063218A (ko) * 2019-09-16 2022-05-17 노파르티스 아게 안정한 농축 방사성 약제학적 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2026083422A1 (en) * 2024-10-20 2026-04-23 Starget Pharma Ltd Cyclic grpr binding peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943561A (en) * 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IE903958A1 (en) 1989-11-06 1991-05-08 Erba Carlo Spa Reduced irreversible bombesin antagonists
WO1993016105A1 (en) 1992-02-07 1993-08-19 Merrell Dow Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
IN2013MN01188A (https=) 2010-11-22 2015-07-10 Piramal Imaging Sa
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) * 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David C. Heimbrook 외. Gastrin Releasing Peptide Antagonists with Improved Potency and Stability. J. Med. Chem. 1991, Vol. 34, pp. 2102-2107*
Wael R. Abd-Elgaliel 외. Design, Synthesis, and Biological Evaluation of an Antagonist-Bombesin Analogue as Targeting Vector. Bioconjugate Chem. 2008, Vol. 19, pp. 2040-2048*

Also Published As

Publication number Publication date
MX362675B (es) 2019-01-30
AU2013323596B2 (en) 2018-03-22
EP2900279B1 (en) 2019-08-14
JP6562838B2 (ja) 2019-08-21
AU2019216714A1 (en) 2019-09-05
WO2014052471A1 (en) 2014-04-03
KR102314293B1 (ko) 2021-10-19
RU2015115529A (ru) 2016-11-20
IL312551A (en) 2024-07-01
JP7534498B2 (ja) 2024-08-14
US12064490B2 (en) 2024-08-20
SI2900279T1 (sl) 2019-12-31
AU2013323596C1 (en) 2020-10-15
IL276300A (en) 2020-09-30
US20200009276A1 (en) 2020-01-09
ES2745635T3 (es) 2020-03-03
CA2886068C (en) 2021-06-22
IL237844B (en) 2018-01-31
BR112015006453A2 (https=) 2017-09-05
IL276300B2 (en) 2024-10-01
JP2019167365A (ja) 2019-10-03
US11083805B2 (en) 2021-08-10
AU2019216714B2 (en) 2021-04-08
US20220008568A1 (en) 2022-01-13
US20180133349A1 (en) 2018-05-17
JP7358430B2 (ja) 2023-10-10
AU2013323596A1 (en) 2015-04-02
US20240366812A1 (en) 2024-11-07
AU2021201914A1 (en) 2021-04-29
EP2900279A1 (en) 2015-08-05
EP3536347A1 (en) 2019-09-11
KR20150090886A (ko) 2015-08-06
CA2886068A1 (en) 2014-04-03
JP2021191800A (ja) 2021-12-16
JP2023126440A (ja) 2023-09-07
LT2900279T (lt) 2019-11-11
US9839703B2 (en) 2017-12-12
HUE045724T2 (hu) 2020-01-28
KR20200139846A (ko) 2020-12-14
IL312551B2 (en) 2025-12-01
US12064489B2 (en) 2024-08-20
MX2015003772A (es) 2015-11-09
RU2693465C2 (ru) 2019-07-03
US20150265732A1 (en) 2015-09-24
AU2018204513B2 (en) 2019-05-23
JP6997135B2 (ja) 2022-02-04
CA3114832A1 (en) 2014-04-03
IL256649A (en) 2018-02-28
RU2019119378A (ru) 2020-10-23
DK2900279T3 (da) 2019-09-30
US12064491B2 (en) 2024-08-20
AU2018204513C1 (en) 2020-10-15
RU2693465C9 (ru) 2020-08-14
JP2015533119A (ja) 2015-11-19
HRP20191620T1 (hr) 2019-12-13
IL256649B (en) 2020-08-31
IL312551B1 (en) 2025-08-01
IL276300B1 (en) 2024-06-01
PT2900279T (pt) 2019-10-14
AU2021201914B2 (en) 2024-09-05
BR112015006453B1 (pt) 2023-10-17
US20210346528A1 (en) 2021-11-11
PL2900279T3 (pl) 2020-05-18
US20210346529A1 (en) 2021-11-11
AU2018204513A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
JP7534498B2 (ja) Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト
Laverman et al. Radiolabelled peptides for oncological diagnosis
García-Garayoa et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
WO2026058257A1 (en) Grpr binding peptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6